2026-01-18 - Analysis Report
**English Report of ABBV Inc.**

**Company Overview:** AbbVie Inc., a multinational biopharmaceutical company.

**Key Metrics:**

* Cumulative Return (ABBV): 175.47%
* Cumulative Return (VOO): 93.36%
* Divergence: 82.80 (66.20%)
* CAGR (2021-2023): 45.0%

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|-------|--------|
| 2016-2018 | 50.0% | 16.0% | 46.0% | 1.0 | 162.9B |
| 2017-2019 | 42.0% | 21.6% | 25.0% | 1.1 | 156.5B |
| 2018-2020 | 4.0% | 21.6% | -17.0% | 0.8 | 189.4B |
| 2019-2021 | 61.0% | 20.5% | 18.0% | 0.7 | 239.3B |
| 2020-2022 | 66.0% | 18.5% | 68.0% | 0.6 | 285.6B |
| 2021-2023 | 45.0% | 18.5% | 44.0% | 0.4 | 273.9B |
| 2022-2024 | 37.0% | 18.9% | 18.0% | 0.3 | 314.1B |
| 2023-2025 | 99.0% | 18.9% | 37.0% | 0.3 | 403.8B |

**Recent Stock Price Fluctuation:**

* Close: $214.35
* Last-market (Previous Close): $215.02
* 5-day SMA: $218.76
* 20-day SMA: $225.01
* 60-day SMA: $225.80

**Technical Indicators:**

* RSI: 34.11
* PPO: -0.56
* Market Risk Indicator (MRI): 0.80 (Neutral Investment Recommended)
* Expected Return: 39.60%
* Recent (20 days) relative divergence change: -6.60 (Worsening)
* 7-day Rank change: 0 (Flat)
* 7-day Dynamic Expected Return change: 0.00 (Flat)

**Recent News & Significant Events:**

* AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
* AbbVie Call Options Spike 2,599%
* AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know
* Assessing AbbVie (ABBV) Valuation After Recent Share Price Weakness
* Fund Update: New $14.2M $ABBV stock position opened by E. Ohman J:or Asset Management AB
* AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 245.04 / 289.00 / 184.00

**Comprehensive Analysis Summary:**

ABBV Inc. has shown significant growth in recent years, with a cumulative return of 175.47%. The stock has been influenced by recent news and events, including a stock dip and a call options spike. Analysts hold a Buy consensus, with a mean opinion of 1.93 (~Buy) and a target price range of $245.04 to $289.00. The Market Risk Indicator is at 0.80, indicating a neutral investment recommendation. Expected returns for the stock are estimated at 39.60%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.